When Was Wegovy Invented — and How Did Semaglutide Become a Weight-Loss Medicine?

You've looked up 'when was Wegovy invented' — here's the honest answer

The question usually arrives because someone has just heard about Wegovy for the first time, often from a friend or a news story, and wonders whether this is genuinely established medicine or something rushed to market. It is a fair thing to ask. The short answer is that the underlying science is old; the brand name Wegovy is relatively new.

The story begins with a lizard. In the 1980s, researchers studying the Gila monster's digestive hormones identified a compound (exendin-4) that mimicked a human gut hormone called GLP-1 (glucagon-like peptide-1). GLP-1 is released when you eat; it signals fullness to the brain, slows how quickly food leaves the stomach, and nudges the pancreas to release insulin. The trouble is that natural GLP-1 breaks down within minutes. The pharmaceutical challenge was engineering a version that survived long enough to be clinically useful. For more on the molecule's origins, the page on who invented semaglutide covers the Novo Nordisk research programme in depth.

Novo Nordisk solved this by attaching a fatty acid chain to the semaglutide molecule, allowing it to bind to albumin in the blood and resist rapid breakdown. The result is a compound stable enough for once-weekly injection. Early clinical work in the 2010s showed impressive glucose control in people with type 2 diabetes, setting the stage for the higher doses that would eventually form the basis of Wegovy.

From diabetes approval to a dedicated weight-loss licence

Semaglutide first reached patients as a diabetes medicine. The 0.5 mg and 1 mg weekly injection (sold as Ozempic) was approved for type 2 diabetes in the US in 2017 and in the UK by the MHRA shortly after. It remains licensed specifically for diabetes, the semaglutide overview explains why Ozempic is not the same product as Wegovy, even though both contain the same active ingredient.

The question of whether higher doses could drive meaningful weight loss in people without diabetes was tested in the STEP clinical trial programme. STEP 1, published in the New England Journal of Medicine (2021), enrolled nearly 2,000 adults with obesity or overweight plus at least one weight-related condition. Participants using semaglutide 2.4 mg weekly alongside lifestyle changes lost around 15% of their body weight on average over 68 weeks, compared with around 2.4% on placebo. These results gave regulators the evidence base to consider a weight-management licence.

The US FDA approved Wegovy in June 2021. The UK's MHRA followed with its own approval in 2023, after independent review of the evidence. NICE then issued its recommendation (TA875) that Wegovy could be used on the NHS, but only for a maximum of two years, within specialist weight management services, and with strict BMI and comorbidity thresholds. The full eligibility picture is set out on the Wegovy treatment page.

What happened after the initial approval, a medicine that kept evolving

Licensing is rarely a single event. Since 2023 the regulatory picture around semaglutide for weight loss has continued to change, and fairly quickly. In January 2026 the MHRA approved a 7.2 mg maintenance dose of Wegovy, with a dedicated single-dose pen following on 14 April 2026, as confirmed by the gov.uk announcement. Trial data for that higher dose showed average weight loss of around 20.7% over 72 weeks, closing the gap with the highest tirzepatide doses. The approved starting point remains 0.25 mg, with the prescriber titrating up over several months.

Then, on 11 June 2026, the MHRA approved an oral Wegovy tablet, a once-daily 25 mg maintenance dose taken first thing in the morning on an empty stomach, waiting at least 30 minutes before any food or drink. This made the UK the first country in Europe to license an oral GLP-1 medicine for weight management. If you want to understand how the approval timeline unfolded chronologically, the page on when semaglutide was approved tracks each regulatory milestone in order.

If you are thinking about whether treatment still makes sense after an extended period, the question of whether Wegovy eventually stops working is worth reading before you start.

One practical habit worth building early: before you order from any online pharmacy, spend thirty seconds checking it on the GPhC register at pharmacyregulation.org. Legitimate UK pharmacies are listed there by name and registration number. It takes less time than reading a single review, and it tells you far more.

Understanding the cost picture is part of planning realistically. Private Wegovy pricing has shifted since Novo Nordisk adjusted list prices, and what different providers include in a headline figure varies considerably. The Wegovy cost page breaks down what is typically included and what is often left out.

What this history means for anyone considering treatment today

A medicine's age is not the same as its safety record, but context matters. Semaglutide has now been used by millions of people worldwide across its diabetes and weight-management indications. The clinical trial programme is extensive, the regulatory reviews were conducted independently by the MHRA, and NICE's appraisal (TA875) scrutinised the evidence before recommending NHS use. That does not mean semaglutide is without risk. Side effects are real, nausea, vomiting, diarrhoea and constipation are the most commonly reported, usually most noticeable at the start of treatment or after a dose increase. More serious but rarer concerns include acute pancreatitis; the MHRA issued a Drug Safety Update on this in January 2026 and advises seeking urgent help for severe stomach pain that spreads to the back.

Wegovy is not licensed for use in pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for anyone under 18. Individual suitability depends on your full medical picture, which is exactly why a prescriber's assessment comes first. The question of when to take Wegovy covers the practical day-to-day detail once a prescriber has confirmed it is right for you, and when to stop Wegovy addresses what the clinical guidance says about long-term use.

If you would like to explore whether semaglutide treatment is appropriate for your situation, nume's prescribers carry out a same-day clinical review of every consultation. You can check your eligibility with a free consultation, no commitment, no subscription, just an honest clinical opinion from a GPhC-registered prescriber.